Oncotarget

Research Perspectives:

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders

Mayumi Naramura _, Scott Nadeau, Bhopal Mohapatra, Gulzar Ahmad, Chandrani Mukhopadhay, Martin Sattler, Srikumar M. Raja, Amarnath Natarajan, Vimla Band and Hamid Band

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2011; 2:245-250. https://doi.org/10.18632/oncotarget.233

Metrics: PDF 2063 views  |   HTML 3117 views  |   ?  


Abstract

Mayumi Naramura1,2, Scott Nadeau1,2, Bhopal Mohapatra1,3, Gulzar Ahmad1, Chandrani Mukhopadhyay1, Martin Sattler5, Srikumar M Raja1, Amarnath Natarajan1,4, Vimla Band1,2, Hamid Band1,2,3

1 Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE

2 Department of Genetics, Cell Biology and Anatomy, College of Medicine, University of Nebraska Medical Center, Omaha, NE

3 Department of Biochemistry & Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE

4 Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE

5 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

Keywords: Cbl, E3 ubiquitin ligase, leukemia, protein tyrosine kinase, signal transduction

Received: March 7, 2011; Accepted: March 20, 2011; Published: March 20, 2011;

Correspondence:

Mayumi Naramura, e-mail:

Hamid Band, e-mail:

Abstract

Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions of Cbl proteins are mediated through their ability to facilitate ubiquitination and thus promote degradation of PTKs. As aberrant activation of PTKs is frequently associated with oncogenesis, it has long been postulated that loss of normal Cbl functions may lead to unregulated activation of PTKs and cellular transformation. In the last few years, mutations in the CBL gene have been identified in a subset of human patients with myeloid malignancies. Here we discuss insights gained from the analyses of Cbl mutants both in human patients and in animal models and propose potential mechanisms of oncogenesis through this pathway.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 233